In November 2022, it received accelerated FDA approval as a monotherapy for treating adults with FRα-positive, platinum-resistant epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer who had previously undergone 1–3 systemic treatment regimens (Heo, 2023). Here, FOLR1 is linked to peritoneum cancer.